Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Home
/
update
/
details

MedGenome Celebrates a Decade of Genomics Innovation

NextEdge Admin

17 Oct 2024

2 min 45 sec

Founded in 2013, MedGenome, a global leader in genomics-driven diagnostics and research, celebrates ten years of transforming healthcare through genomics. To mark this milestone, the company has released a corporate video, *[10 Years of Pioneering Genomics]*, highlighting its decade-long journey. This film honors the efforts of MedGenome’s partners—investors, clinicians, scientists, lab technicians, and over 1,100 employees—who have worked together to advance science and deliver innovative diagnostic solutions. With the hashtag #10yearsofpioneeringgenomics, the company reaffirms its commitment to making quality genetic solutions accessible to all.

Over the past decade, MedGenome has played a pivotal role in advancing precision medicine by developing more than 1,300 high-end genetic tests across key areas such as oncology, reproductive health, infectious diseases, and preventive care. Notable achievements include launching India’s first validated non-invasive prenatal testing (NIPT), liquid biopsy (OncoTrack), and SPIT Seq for detecting drug-resistant tuberculosis. Additionally, MedGenome has sequenced over 350,000 exomes and genomes, providing critical insights into rare and complex diseases.

As a founding member of GenomeAsia 100K, MedGenome has contributed significantly to global research, facilitating advancements in precision medicine. The company has collaborated with institutions like Stanford University, Harvard Medical School, and NIH, leading to groundbreaking discoveries, such as identifying genetic variants linked to cardiovascular and neurological conditions.

Committed to social impact, MedGenome’s HOPE for Rare Diseases Program, in partnership with Twist Bioscience, provides discounted whole exome sequencing for patients from low-income families. The company has also engaged with over 15,000 clinicians and partnered with more than 5,500 hospitals to expand access to affordable genetic testing across India.

Looking ahead, MedGenome aims to further democratize healthcare by leveraging genomics to address unmet needs and improve health outcomes globally.